


Top Gainer and Loser				
Company	CLOSE	YCP	% Change	VOLUME
Top Gainer				
KPPL	24	22	9.05	8,672,448
CRYSTALINS	94	86	8.97	526,431
GEMINISEA	534	491	8.75	126,459
PDL	14	13	8.66	14,341,795
AZIZPIPES	119	111	7.21	648,439
Loser				
KBPPWBIL	62	66	(5.60)	1,253,675
CENTRALPHL	17	18	(5.03)	12,594,363
BATASHOE	928	976	(4.91)	672
FUWANGCER	22	23	(4.33)	9,818,951
BDTHAI	19	20	(3.52)	4,455,791

YCP = Yesterday Closing Price





Top Stocks (Turnover based)

INSTRUMENT	Price	Value (Mn BDT)	Volume
FUWANGCER	22	226	9,818,951
CENTRALPHL	17	224	12,594,363
YPL	31	211	6,818,293
KPPL	24	209	8,672,448
PDL	14	198	14,341,795
ETL	12	144	11,695,718
FUWANGFOOD	31	139	4,427,572
OAL	13	104	7,636,180
BDTHAI	19	90	4,455,791
EMERALDOIL	101	81	790,415

Market Statistics	Today	% Change	World Markets	Exchange Rates
Market Cap (In Mn BDT)	7,719,723	0.04%	Indices	Currency
Total Volume (In Mn BDT)	4,096	18.58%	NASDAQ	USD
DSEX	6,224	0.04%	HANG SENG	GBP
DSES	1,351	0.04%	BSE-SENSEX	EUR
DS-30	2,103	-0.06%		
Market P/E	20.6			

Market Commentary

Today's Market / DSEX (Prime bourse : DSE / Dhaka Stock Exchange Ltd.) ended up 0.04% with 18.58% growth in total turnover. FUWANGCER, CENTRALPHL, YPL, KPPL, PDL stocks dominated today's market turnover. However, IMAMBUTTON was today's best performer having the highest growth of 9.75% from YCP. DSEX reflected a bullish mode through the day resulting in 100 issues declined out of 319 total issues traded.



TAMIJTEX
Dividend Declaration

The Board of Directors has recommended 20% Cash Dividend for general shareholders (excluding Sponsors and Directors) for the year ended June 30, 2023. The Sponsors and Directors hold 18,410,596 shares out of total 30,064,767 shares of the company and Cash Dividend payable to general shareholders is Tk. 23,308,342.00. Date of AGM: 31.12.2023, Time: 11:30 AM, Venue: Digital Platform. Record Date: 10.12.2023.

JANATAINS
Credit Rating Result

National Credit Ratings Limited (NCRL) has assigned the surveillance entity rating of the Company as "AAA" in the long term and "ST-1" in the short term along with Stable outlook based on audited financial statements as on December 31, 2022 and other relevant quantitative as well as qualitative information up to the date of rating declaration.

NITOLINS
Credit Rating Result

Credit Rating Information and Services Limited (CRISL) has assigned rating of the Company as "AA+" in the long term along with Stable outlook in consideration of its audited financials up to December 31, 2022 also unaudited financials up to September 30, 2023 and other relevant quantitative as well as qualitative information up to the date of rating declaration.

NAHEEACP
Credit Rating Result

National Credit Ratings Limited (NCRL) has assigned the surveillance entity rating of the Company as "A-" in the long term and "ST-3" in the short term along with Developing outlook based on audited financial statements as on June 30, 2023 and other relevant quantitative as well as qualitative information up to the date of rating declaration.

MONNOAGML
Credit Rating Result

WASO Credit Rating Company (BD) Ltd. (WCRL) has assigned the surveillance entity rating of the Company as "A-" for long term and "ST-3" for short term along with Stable outlook based on audited financial statements of FY2023 and other relevant qualitative and quantitative information.

Other News Today

Square Pharma eyes expansion by setting up subsidiary in Philippines - Source: The Financial Express

Square Pharmaceuticals is going to invest \$2.5 million to set up a subsidiary in the Philippines to grab a higher share of the country's drug market. The subsidiary, Samson Pharma Inc is expected to begin its operations by April 2024, to market and distribute pharmaceutical products that are allowed in the Philippines, according to a stock exchange filing on Tuesday. The board of Square Pharma said the subsidiary would be funded at a debt-equity ratio of 60:40, meaning 60 per cent or \$ 1.5 million would come from debt financing - bank loans - while the remaining 40 per cent or \$ 1 million would be invested from its own source. Square Pharma, Bangladesh's largest drug maker that mainly caters to the domestic need, considers the Philippines as a potential export destination for it fulfills the demand for medicines largely through imports from different countries, including India. Muhammad Zahangir Alam, chief financial officer of Square Pharma, said the Philippines met half of its medicine requirement through imports. Of its total drug requirement, the Philippines imports 20 per cent from India. Ten companies from Bangladesh, including Square Pharma, have already been exporting medicines to the country, said Mr Alam. "We have a full range of product offerings. We are opening the company in the Philippines so we can ensure optimum use of the business opportunities." The subsidiary in the Philippines will not be the first overseas venture of Square Pharma. It set up a plant at an export processing zone in Nairobi, Kenya and began commercial manufacturing there in January this year. Having seen the demand for its products rising, Square Pharma also signed a new deal for contract manufacturing with General Pharmaceuticals Dhaka, according to the Tuesday filing. Earlier, the drug maker finalised several contracts with Aristopharma, Euro Pharma, Renata Oncology, and Apex Pharma not only to expand production but also introduce new products. The drug manufacturer, which increased its market share to more than 20 per cent in FY23 from over 18 per cent a year ago in Bangladesh, seeks to further bolster its position in the domestic market. Though Square Pharma's business mainly focuses on the local market, it has gained a foothold in the export market too, having supplied drugs to well-regulated markets, such as the US and the EU nations. It started exporting medicines in 1987, and over time it has gained capacity to export antibiotics and other pharmaceutical products to more than 42 countries. Meanwhile, the drug maker witnessed the highest-ever quarterly profit in July-September this year, driven by a spike in the demand for dengue-related drugs. The company secured a consolidated profit of more than Tk 6 billion in the first quarter of FY24, a 9.10 per cent increase from the same quarter a year before. Square Pharma, the flagship company of Square Group, also registered a 15 per cent year-on-year sales growth to Tk 18.46 billion in the quarter through September. It made a record annual profit of around Tk 19 billion in FY23, driven by record sales. The board declared the highest-ever cash dividend of 105 per cent for FY23.